What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 2.8% in the morning session after RBC Capital reiterated an "Outperform" rating and a $210 price target on the stock, naming it a ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases.

Biogen Inc. stock reached a 52-week high of 185.59 USD, marking a significant milestone for the biotechnology company. According to InvestingPro data, the stock is trading at 184.58 USD, just 0.99% ...

With a market cap of $20.4 billion, Biogen Inc. (BIIB) is a leading biopharmaceutical company specializing in treatments for neurological, rare, and immunological diseases. Headquartered in Cambridge, ...

Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and ...

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...

Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm ...